Codexis, Inc. (CDXS)

Codexis reported robust fourth-quarter 2025 results that surpassed expectations, with an 81% year-over-year revenue increase primarily driven by a technology transfer agreement with Merck, resulting in a stock gain of +34.7%. A $37.8 million technology transfer agreement with Merck significantly contributed to the Q4 2025 revenue increase. The Q3 2025 earnings report had a negative impact on the stock, resulting in a -16.9% move due to weaker revenue, restructuring, workforce reductions, and a large quarterly net loss. The Q2 2025 earnings report had a positive impact, with a +1.6% stock move, driven by a revenue beat, higher margins, and strengthened cash through an ATM and loan. Over the past month (leading up to March 20, 2026), the stock increased by 36.75%, but over the last 12 months, the stock's price decreased by 37.25%.

While specific details on the seasonality of demand for Codexis's products and services are not explicitly provided, the company's investor relations materials do offer tools to identify seasonal patterns in monthly stock returns. The company's revenue is expected to be more heavily weighted towards the second half of 2026 versus the first half, similar to quarterly trends observed in 2025, suggesting some internal seasonality in their revenue recognition or project completion, which could be related to demand or project timelines.

Codexis, Inc. is a protein-engineering company providing enzyme-based technology solutions across multiple industries, including pharmaceuticals, fine chemicals, biotherapeutics, food and beverage, and agriculture. The company operates within the Healthcare sector, specifically in the Biotechnology and Medical Research industry. Codexis leverages its CodeEvolver® technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. Its major products and business areas include biocatalysts and pharmaceutical intermediates, Codex Biocatalyst Panels and Kits, the ECO Synthesis™ Manufacturing Platform, an early-stage enzyme therapeutic product candidate, and enzymes for nucleic acid synthesis.

Codexis, Inc. is headquartered in Redwood City, California, U.S. The company's operations and commercialization efforts extend globally, with key geographic presences in the Americas, Middle East and Africa, Europe, Asia-Pacific (APAC). More specifically, it serves markets in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The Americas region is a significant source of revenue for the company.

Codexis has a reputation as a "gold-standard partner" in the industry, driven by its focus on sustainable enzyme engineering and advancements in RNA therapeutics. The company's expansion, internalized supply chain, and strategic partnerships are seen as setting the stage for accelerated growth and industry-leading profitability. The launch of its ECO Synthesis platform in 2025 is expected to enhance revenue growth by securing new contracts and expanding into pharma and biotech segments, further solidifying its reputation. The strong financial performance and optimistic projections for 2026, particularly the significant revenue increase driven by the Merck technology transfer agreement, likely bolstered investor and industry confidence. The company has demonstrated tangible and significant interest from customers in its ECO Synthesis platform for powerful siRNA therapeutics, showcasing its leadership in biocatalytic enzyme innovation.

Codexis, Inc. is primarily owned by institutional shareholders and company insiders. As of April 8, 2026, there are 130 institutional owners and shareholders holding a total of 64,892,509 shares. Major institutional owners include Standard Life Aberdeen plc, BlackRock, Inc., Opaleye Management Inc., Vanguard Group Inc, Nantahala Capital Management, LLC, Telemark Asset Management, LLC, Ameriprise Financial Inc, Millennium Management Llc, Prescott Group Capital Management, L.l.c., and Geode Capital Management, Llc. Significant individual/insider owners include Vivo Ventures VII LLC, owning 17.78% of the company's shares, and Equilon Enterprises LLC, owning 12.27% of the company's shares.